EUVIMEDEUVIMED entdecken
Crossref

Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates

David Luque Paz iD, Adrien Turban, François Guérin iD, Malo Penven iD, Matthieu Revest, Cristina García-de-la-Mària iD, José M Miró iD, Pierre Tattevin iD, Vincent Cattoir iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf262 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von David Luque Paz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Pontchaillou University Hospital, Rennes, France. Hauptthemen laut MEDLINE: Enterococcus faecalis, Teicoplanin, beta-Lactams, Anti-Bacterial Agents. Die Arbeit nennt 25 Literaturangaben. Gefördert von: RICAI International Mobility Grant 2024, the Rennes University Hospital International Mobility Grant 2022, the Collège Doctoral de Bretagne Outgoing International Mobility Programme 2024.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There are limited in vitro synergistic studies on dalbavancin against enterococci. We aimed to assess the in vitro activity of dalbavancin against Enterococcus faecalis strains, and to explore the interaction between dalbavancin and β-lactams.

Methods

MIC and MBC values were determined against a panel of 10 clinical isolates and two reference strains of E. faecalis. Checkerboard assays were conducted for the initial screening for additive, synergistic or antagonistic effect between dalbavancin and different classes of antibiotics. Thereafter, time–kill (TK) assays with β-lactams were performed to confirm the results.

Results

All strains were tolerant to dalbavancin (MBC/MIC ratios >32). For 11 of the 12 strains tested, a synergy was found in TK assays between dalbavancin (0.5 × MIC) and each β-lactam (0.25 × MIC), namely amoxicillin, cefazolin, ceftriaxone, cefepime, ceftobiprole, ertapenem and meropenem. Paradoxically, we systematically found reduced efficacy of β-lactams in combination with dalbavancin at concentrations greater than or equal to MIC. At these concentrations, TK assays demonstrated that a combination with dalbavancin resulted in an antagonism of amoxicillin (8/12 strains), ceftobiprole (10/12 strains) and ertapenem (5/12 strains) activities. Dalbavancin alone at 32 mg/L or in combination with amoxicillin at 2 mg/L induced a slow bacterial reduction (median decrease of 0.4 log10 at 24 h for both regimens), whereas amoxicillin alone at 2 mg/L reduced the E. faecalis inoculum by 3.2 log10 (IQR, 3.1–3.4).

Conclusions

Dalbavancin exhibits poor activity against E. faecalis, and impairs the activity of β-lactams, especially amoxicillin. Dalbavancin should be used with caution in the treatment of E. faecalis infective endocarditis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterococcus faecalisTeicoplaninbeta-LactamsAnti-Bacterial AgentsGram-Positive Bacterial InfectionsDrug SynergismEndocarditis, BacterialMicrobial Sensitivity TestsHumansDrug InteractionsMicrobial Viability

Substanzen

Teicoplaninbeta-LactamsAnti-Bacterial Agentsdalbavancin

Autor:innen und Institutionen

  • Infectious Diseases Department, Pontchaillou University Hospital, Rennes, France.
  • Inserm U1230 Bacterial RNAs and Medicine, University of Rennes, Rennes, France.
  • Department of Bacteriology, University Hospital of Rennes, Rennes, France.
  • National Reference Center for Enterococci, University Hospital of Rennes, Rennes, France.
  • Experimental Endocarditis Laboratory, Hospital Clínic, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
  • Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

ORCID-Profile: David Luque Paz, François Guérin, Malo Penven, Cristina García-de-la-Mària, José M Miró, Pierre Tattevin, Vincent Cattoir

Förderung

  • RICAI International Mobility Grant 2024
  • the Rennes University Hospital International Mobility Grant 2022
  • the Collège Doctoral de Bretagne Outgoing International Mobility Programme 2024
  • Fundació Clínic per a la Recerca Biomèdica-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FCRB/IDIBAPS)
  • IDIBAPS
  • Fundació Clínic per a la Recerca Biomèdica–Institut d’Investigacions Biomèdiques August Pi i Sunyer

Zitieren

APA

Luque Paz, D., Turban, A., Guérin, F., Penven, M., Revest, M., García-de-la-Mària, C., Miró, J. M., Tattevin, P., & Cattoir, V. (2025). Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf262

Vancouver

Luque Paz D, Turban A, Guérin F, Penven M, Revest M, García-de-la-Mària C, et al. Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf262

BibTeX
@article{LuquePaz2025,
  author = {Luque Paz, David and Turban, Adrien and Guérin, François and Penven, Malo and Revest, Matthieu and García-de-la-Mària, Cristina and Miró, José M and Tattevin, Pierre and Cattoir, Vincent},
  title = {Paradoxical interaction between dalbavancin and β-lactams against endocarditis-associated Enterococcus faecalis clinical isolates},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf262}
}
Kostenlos starten →